We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Vascular Occluder Targets Wide Range of Peripheral Arteries

By HospiMedica International staff writers
Posted on 30 Dec 2020
A new platform provides interventional physicians with “one-and-done” solution for the occlusion of a peripheral arterial targets. More...


The Okami Medical LOBO (LOw-profile Braided Occluder) system combines neurovascular-derived HDBRAID technology with a patented design so as to create a highly occlusive structure for fast and efficient closure of blood vessels throughout the body. HDBRAID allows braided devices to be made with wires less than 20 microns in diameter, about ¼ the thickness of a human hair. This results in over 5,000 pores, with four times greater pore density than conventional occluders, which significantly reduces flow and accelerates hemostasis and thrombosis.

Features include a dense pore structure for rapid occlusion of a wide range of vessels; microcatheter delivery with instantaneous mechanical detachment; excellent trackability, even in small, tortuous vessels; conformance to curved vessels and expansion to accessible anatomical locations; retrievability prior to release; high stability following placement; and no spinnaker effect. The system includes the LOBO-5, intended for use in 3-5 mm diameter vessels, and the LOBO-3, intended for use in 1.5-3 mm vessels. It is not indicated for use in blood vessels where crush or bend forces are anticipated, such as joint areas and superficial vasculature.

“Guided by world-class physician collaborators, Okami is committed to addressing numerous challenging aspects of peripheral vascular occlusion,” said Bob Rosenbluth, PhD, president and CEO of Okami Medical. “LOBO-3 and LOBO-5, to be followed by LOBO-7 and LOBO-9, are designed and built to enable fast, predictable and complete occlusion of a diverse set of vascular targets, without the need for multiple embolic devices.”

Peripheral vascular occlusion is intended for the treatment of hemorrhages, aneurysms, and tumor isolation, including nephroma, hematoma, and other vascular malformations, and uterine fibroids, among other conditions.

Related Links:
Okami Medical


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Short Phlebotomy Cart
MSWA-3469-WHT
New
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: New clinical guidance suggests treatments to prevent blood clots in CLTI patients after leg artery procedures (Photo courtesy of Shutterstock)

Stronger Blood Clot Prevention Measures Needed After Leg Artery Procedures in High-Risk Patients

Chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), significantly reduces blood flow to the legs and feet. Despite undergoing lower limb revascularization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.